[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 662
Citations 0
In This Issue of JAMA Surgery
December 2013


JAMA Surg. 2013;148(12):1081-1083. doi:10.1001/jamasurg.2013.2208

Transcatheter aortic valve replacement (TAVR) is approved for patients for whom traditional AVR poses high or prohibitive risk. Omer and colleagues evaluated the early results of one the first Veteran Affairs (VA) TAVR programs, in which19 transfemoral TAVRs were performed. There was no operative (30-day) mortality and a low incidence of major morbidity. Thus, TAVR can be performed safely and with good outcomes at a VA facility with adequate expertise and resources.

Invited Commentary

Whether hospital and surgeon volumes have an association with readmission among patients undergoing pancreatoduodenectomy is not known. Using the Surveillance, Epidemiology, and End Results (SEER)–Medicare data, Hyder and colleagues examined in-hospital morbidity, mortality, and procedure volumes relative to 30-day readmission. Nearly 1 in 5 patients were readmitted following pancreatoduodenectomy. Although differences in readmission were attributable to differences among hospitals, the largest share of variation was found at the patient level.